Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
48.5M
-
Number of holders
-
41
-
Total 13F shares, excl. options
-
27.7M
-
Shares change
-
+3.79M
-
Total reported value, excl. options
-
$107M
-
Value change
-
+$14.9M
-
Put/Call ratio
-
0.03
-
Number of buys
-
23
-
Number of sells
-
-9
-
Price
-
$3.86
Significant Holders of Werewolf Therapeutics, Inc. - Common Stock (HOWL) as of Q4 2023
46 filings reported holding HOWL - Werewolf Therapeutics, Inc. - Common Stock as of Q4 2023.
Werewolf Therapeutics, Inc. - Common Stock (HOWL) has 41 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.7M shares
of 48.5M outstanding shares and own 57.04% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (6.14M shares), MPM ASSET MANAGEMENT LLC (4.28M shares), PFM Health Sciences, LP (3.47M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.03M shares), MPM BioImpact LLC (2.39M shares), BANK OF AMERICA CORP /DE/ (2.1M shares), Rubric Capital Management LP (1.94M shares), VANGUARD GROUP INC (873K shares), SPHERA FUNDS MANAGEMENT LTD. (627K shares), and DC Funds, LP (589K shares).
This table shows the top 41 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.